公开(公告)号：US20190282608A1

公开(公告)日：2019-09-19

申请号：US16424747

申请日：2019-05-29

Applicant: Cytosorbents Corporation

Inventor： Phillip P. Chan ,  Wei-Tai Young ,  Vincent J. Capponi ,  Thomas D. Golobish ,  Humayra Begum Ali

IPC: A61K31/745 ,  A61K47/58 ,  A61K31/75 ,  A61K9/00 ,  C08J9/26 ,  C08F212/36 ,  B01J20/28 ,  A61K9/16 ,  B01J20/26 ,  B01J20/30 ,  A61K31/74 ,  A61K9/50

Abstract: The present invention concerns methods of administering a therapeutically effective dose of a sorbent for an inflammatory mediator to a patient where the inflammatory mediator is one or more of enzymes, cytokines, prostaglandins, eicosanoids, leukotrienes, kinins, complement, coagulation factors, endotoxins, enterotoxins, lipopolysaccharide, cell fragments, bile salts, fatty acids, phospholipids, interferon and immunomodulatory antibodies, biologics or drugs.

公开(公告)号：US10314859B2

公开(公告)日：2019-06-11

申请号：US15886978

申请日：2018-02-02

Applicant: Cytosorbents Corporation

Inventor： Humayra Begum Ali ,  Thomas D. Golobish ,  Vincent J. Capponi ,  Phillip P. Chan ,  Wei Tai Young ,  Andrew Robert Scheirer

IPC: A61M31/00 ,  A61K31/74 ,  A61K31/765 ,  A61P1/06 ,  A61P1/04 ,  A61P1/00 ,  A61K9/00 ,  A61K31/79 ,  A61K31/75

Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).

公开(公告)号：US10034894B2

公开(公告)日：2018-07-31

申请号：US15635517

申请日：2017-06-28

Applicant: CytoSorbents Corporation

Inventor： Phillip P. Chan ,  Wei-Tai Young ,  Vincent J. Capponi ,  Thomas D. Golobish ,  Humayra Begum Ali

IPC: A61K31/745 ,  A61K9/16 ,  A61K9/50 ,  C08J9/26 ,  B01J20/26 ,  B01J20/30 ,  A61K9/00 ,  B01J20/28 ,  C08F212/36 ,  A61K31/74 ,  A61K31/75 ,  A61K47/58

CPC classification number: A61K31/745 ,  A61K9/0053 ,  A61K9/16 ,  A61K9/50 ,  A61K31/74 ,  A61K31/75 ,  A61K47/58 ,  B01J20/261 ,  B01J20/28004 ,  B01J20/28073 ,  B01J20/28076 ,  B01J20/3064 ,  C08F212/36 ,  C08J9/26 ,  C08J2201/0444 ,  C08J2207/10 ,  C08J2325/02 ,  Y02A50/406 ,  Y02A50/411

Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

公开(公告)号：US20180169138A1

公开(公告)日：2018-06-21

申请号：US15886978

申请日：2018-02-02

Applicant: Cytosorbents Corporation

Inventor： Humayra Begum Ali ,  Thomas D. Golobish ,  Vincent J. Capponi ,  Phillip P. Chan ,  Wei Tai Young ,  Andrew Robert Scheirer

IPC: A61K31/765 ,  A61K9/00

CPC classification number: A61K31/765 ,  A61K9/0053 ,  A61K31/75 ,  A61K31/79 ,  A61P1/00 ,  A61P1/04 ,  A61P1/06

Abstract: Disclosed herein are compositions and methods for preventing or treating acute or chronic oral mucositis, esophagitis, enteritis, colitis, or gastrointestinal acute radiation syndrome (GI-ARS) caused by radiation exposure, using one or more enteron sorbent polymers administered gastrointestinally (e.g. orally, via feeding or gastric tube, via ostomy, or rectally).

公开(公告)号：US20170296574A1

公开(公告)日：2017-10-19

申请号：US15635517

申请日：2017-06-28

Applicant: CytoSorbents Corporation

Inventor： Phillip P. Chan ,  Wei-Tai Young ,  Vincent J. Capponi ,  Thomas D. Golobish ,  Humayra Begum Ali

IPC: A61K31/745 ,  A61K9/16 ,  A61K9/50 ,  C08J9/26 ,  B01J20/26 ,  B01J20/30 ,  A61K9/00 ,  B01J20/28 ,  C08F212/36

CPC classification number: A61K31/745 ,  A61K9/0053 ,  A61K9/16 ,  A61K9/50 ,  A61K31/74 ,  A61K31/75 ,  A61K47/58 ,  B01J20/261 ,  B01J20/28004 ,  B01J20/28073 ,  B01J20/28076 ,  B01J20/3064 ,  C08F212/36 ,  C08J9/26 ,  C08J2201/0444 ,  C08J2207/10 ,  C08J2325/02 ,  Y02A50/406 ,  Y02A50/411

Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.